glp-1 long term use As receptor agonists continue expanding across obesity, diabetes, fatty liver disease, and cardiometabolic care, clinicians are increasingly confronting a pressing question: Does long-term lead to tolerance, or do apparent “diminishing 🧠 Researchers are exploring whether

A central role for JNK in obesity and insulin resistance Jiro Hirosumi, Gurol Tuncman, Lufen Chang

411 Therapeutic strategies involving the blockade of IL-1 signaling to inhibit Nlrp3-dependent B cell accumulation or the targeted depletion of B cells within adipose tissue via anti-CD20 antibodies have been shown to mitigate metabolic dysfunction in aged AT

Bliss TW, Dohms JE, Emara MG, Keeler CL Jr

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders

To add value, we further break down our analytics for you so that improving your operational effectiveness

Place de lEcole-de-Medicine (1885)